Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors Academic Article uri icon

Overview

MeSH Major

  • Aniline Compounds
  • Genes, bcl-2
  • Neoplasms
  • Small Cell Lung Carcinoma
  • Sulfonamides

abstract

  • Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4668282

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.31.6208

PubMed ID

  • 21282543

Additional Document Info

start page

  • 909

end page

  • 16

volume

  • 29

number

  • 7